216 related articles for article (PubMed ID: 16111748)
1. Functional integrity in vitro of hematopoietic progenitor cells from patients with chronic myeloid leukemia that have achieved hematological remission after different therapeutic procedures.
Chávez-González A; Ayala-Sánchez M; Sánchez-Valle E; Ruiz-Sánchez E; Arana-Trejo RM; Vela-Ojeda J; Mayani H
Leuk Res; 2006 Mar; 30(3):286-95. PubMed ID: 16111748
[TBL] [Abstract][Full Text] [Related]
2. Severe functional alterations in vitro in CD34(+) cell subpopulations from patients with chronic myeloid leukemia.
Chávez-González A; Rosas-Cabral A; Vela-Ojeda J; González JC; Mayani H
Leuk Res; 2004 Jun; 28(6):639-47. PubMed ID: 15120942
[TBL] [Abstract][Full Text] [Related]
3. Preferential sequestration in vitro of BCR/ABL negative hematopoietic progenitor cells among cytokine nonresponsive CML marrow CD34+ cells.
Veena P; Cornetta K; Davidson A; Agüero B; McMahel J; Traycoff CM; Srour EF
Bone Marrow Transplant; 1997 Jun; 19(12):1213-21. PubMed ID: 9208115
[TBL] [Abstract][Full Text] [Related]
4. Eilatin: a novel marine alkaloid inhibits in vitro proliferation of progenitor cells in chronic myeloid leukemia patients.
Einat M; Lishner M; Amiel A; Nagler A; Yarkorli S; Rudi A; Kashman Y; Markel D; Fabian I
Exp Hematol; 1995 Dec; 23(14):1439-44. PubMed ID: 8542929
[TBL] [Abstract][Full Text] [Related]
5. Peripheral blood progenitor cell collection in chronic myeloid leukemia patients with complete cytogenetic response after treatment with imatinib mesylate.
Perseghin P; Gambacorti-Passerini C; Tornaghi L; Dassi M; Pioltelli P; Parma M; Colnaghi F; Giudici G; Elli E; Fumagalli M; Ponchio L; Biondi A; Pogliani EM
Transfusion; 2005 Jul; 45(7):1214-20. PubMed ID: 15987369
[TBL] [Abstract][Full Text] [Related]
6. Early allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era: a preliminary assessment.
Simon W; Segel GB; Lichtman MA
Blood Cells Mol Dis; 2006; 37(2):116-24; discussion 125-7. PubMed ID: 16904348
[TBL] [Abstract][Full Text] [Related]
7. Imatinib use either pre- or post-allogeneic hematopoietic cell transplantation (allo-HCT) does not increase cardiac toxicity in chronic myelogenous leukemia patients.
Burke MJ; Trotz B; Luo X; Weisdorf DJ; Baker KS; Wagner JE; Verneris MR
Bone Marrow Transplant; 2009 Aug; 44(3):169-74. PubMed ID: 19204709
[TBL] [Abstract][Full Text] [Related]
8. L-selectin expression is low on CD34+ cells from patients with chronic myeloid leukemia and interferon-a up-regulates this expression.
Martín-Henao GA; Quiroga R; Sureda A; González JR; Moreno V; García J
Haematologica; 2000 Feb; 85(2):139-46. PubMed ID: 10681720
[TBL] [Abstract][Full Text] [Related]
9. Differential effect of type I interferons on hematopoietic progenitor cells: failure of interferons to inhibit IL-3-stimulated normal and CML myeloid progenitors.
Després D; Goldschmitt J; Aulitzky WE; Huber C; Peschel C
Exp Hematol; 1995 Dec; 23(14):1431-8. PubMed ID: 8542928
[TBL] [Abstract][Full Text] [Related]
10. Telomerase activity and telomere length in acute and chronic leukemia, pre- and post-ex vivo culture.
Engelhardt M; Mackenzie K; Drullinsky P; Silver RT; Moore MA
Cancer Res; 2000 Feb; 60(3):610-7. PubMed ID: 10676644
[TBL] [Abstract][Full Text] [Related]
11. Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up.
Palandri F; Castagnetti F; Testoni N; Luatti S; Marzocchi G; Bassi S; Breccia M; Alimena G; Pungolino E; Rege-Cambrin G; Varaldo R; Miglino M; Specchia G; Zuffa E; Ferrara F; Bocchia M; Saglio G; Pane F; Alberti D; Martinelli G; Baccarani M; Rosti G;
Haematologica; 2008 Dec; 93(12):1792-6. PubMed ID: 18838477
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of imatinib in patients with chronic myeloid leukemia and complete or near-complete cytogenetic response to interferon-alpha.
Branford S; Hughes T; Milner A; Koelmeyer R; Schwarer A; Arthur C; Filshie R; Moreton S; Lynch K; Taylor K
Cancer; 2007 Aug; 110(4):801-8. PubMed ID: 17607681
[TBL] [Abstract][Full Text] [Related]
13. Potent antileukemic activity of the novel agents norsegoline and dibezine.
Einat M; Nagler A; Lishner M; Amiel A; Yarkoni S; Rudi A; Gellerman G; Kashman Y; Fabian I
Clin Cancer Res; 1995 Aug; 1(8):823-9. PubMed ID: 9816051
[TBL] [Abstract][Full Text] [Related]
14. Chronic myeloid leukemia after treatment of lymphoid malignancies: response to imatinib mesylate and favorable outcomes in three patients.
Ramanarayanan J; Dunford LM; Baer MR; Sait SN; Lawrence W; McCarthy PL
Leuk Res; 2006 Jun; 30(6):701-5. PubMed ID: 16330096
[TBL] [Abstract][Full Text] [Related]
15. In vivo effects of imatinib mesylate on human haematopoietic progenitor cells.
Agis H; Jaeger E; Doninger B; Sillaber C; Marosi C; Drach J; Schwarzinger I; Valent P; Oehler L
Eur J Clin Invest; 2006 Jun; 36(6):402-8. PubMed ID: 16684124
[TBL] [Abstract][Full Text] [Related]
16. Characterization and selection of benign stem cells in chronic myeloid leukemia.
Lemoli RM
Haematologica; 1993; 78(6):393-400. PubMed ID: 8175034
[TBL] [Abstract][Full Text] [Related]
17. Growth factor stimulation reduces residual quiescent chronic myelogenous leukemia progenitors remaining after imatinib treatment.
Holtz M; Forman SJ; Bhatia R
Cancer Res; 2007 Feb; 67(3):1113-20. PubMed ID: 17283145
[TBL] [Abstract][Full Text] [Related]
18. In vitro functional alterations in the hematopoietic system of adult patients with acute lymphoblastic leukemia.
Martínez-Jaramillo G; Vela-Ojeda J; Sánchez-Valle E; Montesinos JJ; Mayani H
Leuk Res; 2007 Jan; 31(1):83-9. PubMed ID: 16769114
[TBL] [Abstract][Full Text] [Related]
19. Imatinib synergizes with donor lymphocyte infusions to achieve rapid molecular remission of CML relapsing after allogeneic stem cell transplantation.
Savani BN; Montero A; Kurlander R; Childs R; Hensel N; Barrett AJ
Bone Marrow Transplant; 2005 Dec; 36(11):1009-15. PubMed ID: 16205732
[TBL] [Abstract][Full Text] [Related]
20. [Therapy of chronic myelogenous leukemia in 2004].
Hochhaus A; Berger U; Hehlmann R
Dtsch Med Wochenschr; 2004 Oct; 129(40):2122-7. PubMed ID: 15455305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]